UPDATE 3-Geron discontinues late-stage trial of blood cancer drug, shares plunge

3

* Committee says trial was unlikely to meet overall survival goal * Higher, more frequent dosing showed no new safety concerns, TD Cowen says * Rytelo generated $57.5 million in second-quarter revenue

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)